Meta-Analysis and Cost-Effectiveness Analysis of Insulin Glargine 100 U/mL Versus Insulin Degludec for the Treatment of Type 2 Diabetes in China-Reference-Cited by-同舟云学术

Meta-Analysis and Cost-Effectiveness Analysis of Insulin Glargine 100 U/mL Versus Insulin Degludec for the Treatment of Type 2 Diabetes in China

Published:2019-09-03 Issue:5 Volume:10 Page:1969-1984
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

Su Wen,Li Chaoyun,Zhang Lei,Lin Ziyi,Tan Jun,Xuan Jianwei

Funder

Sanofi China Investment Company

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13300-019-00683-2.pdf

Reference52 articles.

1. Hu H, Sawhney M, Shi L, Duan S. A systematic review of the direct economic burden of type 2 diabetes in China. Diabetes Ther. 2015;6(1):7–16. https://doi.org/10.1007/s13300-015-0096-0.

2. World Health Organization. Global report on diabetes. Geneva: World Health Organization. https://www.who.int/substance_abuse/publications/global_alcohol_report/en/.. Accessed 8 Aug 2018.

3. Wang L, Gao PZM. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA. 2017;317(24):2515–23. https://doi.org/10.1001/jama.2017.7596.

4. International Diabetes Federation. IDF diabetes atlas 8th edition. Brussels: International Diabetes Federation. https://diabetesatlas.org/resources/2017-atlas.html. Accessed 8 Aug 2018.

5. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2008;387(10027):1513–30. https://doi.org/10.1016/s0140-6736(16)00618-8.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review;JBI Evidence Synthesis;2024-07-29

2. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients;Diabetology & Metabolic Syndrome;2023-08-19

3. Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China;Diabetes Therapy;2022-11-22

4. Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes;Frontiers in Public Health;2022-10-18

5. Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China;Diabetes Therapy;2022-08-08